Kulasekararaj, A., Griffin, M., Langemeijer, S., Usuki, K., Kulagin, A., Ogawa, M., . . . MEDICINE. (2023). Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies. Wiley.
Chicago Style CitationKulasekararaj, AG, et al. Long-term Safety and Efficacy of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: 2-year Results From Two Pivotal Phase 3 Studies. Wiley, 2023.
MLA CitationKulasekararaj, AG, et al. Long-term Safety and Efficacy of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: 2-year Results From Two Pivotal Phase 3 Studies. Wiley, 2023.
Warning: These citations may not always be 100% accurate.